Review Article| Volume 67, ISSUE 1, P1-11, January 2023

Masticatory Myofascial Pain Disorders

Published:October 26, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Dental Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fillingim R.B.
        • Ohrbach R.
        • Greenspan J.D.
        • et al.
        Psychological factors associated with development of TMD: the OPPERA prospective cohort study.
        J Pain. 2013; 14: T75-T90
        • Klasser G.D.
        • Almoznino G.
        • Fortuna G.
        Sleep and orofacial pain.
        Dent Clin North Am. 2018; 62: 629-656
        • Lobbezoo F.
        • Ahlberg J.
        • Glaros A.G.
        • et al.
        Bruxism defined and graded: an international consensus.
        J Oral Rehabil. 2013; 40: 2-4
        • Fernandez-Nunez T.
        • Amghar-Maach S.
        • Gay-Escoda C.
        Efficacy of botulinum toxin in the treatment of bruxism: systematic review.
        Med Oral Patol Oral Cir Bucal. 2019; 24: e416-e424
        • Kirkland A.E.
        • Sarlo G.L.
        • Holton K.F.
        The role of magnesium in neurological disorders.
        Nutrients. 2018; 10: 730
        • Holland S.
        • Silberstein S.D.
        • Freitag F.
        • et al.
        Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.
        Neurology. 2012; 78: 1346-1353
        • Evers S.
        • Afra J.
        • Frese A.
        • et al.
        EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.
        Eur J Neurol. 2009; 16: 968-981
        • Burch R.
        Migraine and tension-type headache: diagnosis and treatment.
        Med Clin North Am. 2019; 103: 215-233
        • Haviv Y.
        • Zini A.
        • Sharav Y.
        • et al.
        Nortriptyline compared to amitriptyline for the treatment of persistent masticatory myofascial pain.
        J Oral Facial Pain Headache. 2019; 33: 7-13
        • Scrivani S.J.
        • Keith D.A.
        • Kaban L.B.
        Medical progress: temporomandibular disorders.
        N Engl J Med. 2008; 359: 2693-2705
        • LeResche L.
        Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors.
        Crit Rev Oral Biol Med. 1997; 8: 291-305
        • Leresche L.
        • Drangsholt M.
        Epidemiology of orofacial pain: prevalence, incidence, and risk factors.
        in: Sessle B.J. Lavigne G.J. Lund J.P. Orofacial pain: from basic science to clinical management. 2nd edition. Quintessence Publishing, Chicago2008: 13-18
        • Manfredini D.
        • Piccotti F.
        • Ferronato G.
        • et al.
        Age peaks of different RDC/TMD diagnoses in a patient population.
        J Dent. 2010; 38: 392-399
        • Schiffman E.
        • Ohrbach R.
        • Truelove E.
        • et al.
        Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD consortium network∗ and orofacial pain special interest groupdagger.
        J Oral Facial Pain Headache. 2014; 28: 6-27
        • de Leeuw R.
        • Klasser G.
        Orofacial pain: guidelines for assessment, diagnosis and management.
        6th edition. Quintessence Publishing Co, Inc, Hanover Park, IL2018: 143-207
      1. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition.
        Cephalalgia. 2018; 38: 1-211
      2. International classification of orofacial pain, 1st edition (ICOP).
        Cephalalgia. 2020; 40: 129-221
        • Lorduy K.M.
        • Liegey-Dougall A.
        • Haggard R.
        • et al.
        The prevalence of comorbid symptoms of central sensitization syndrome among three different groups of temporomandibular disorder patients.
        Pain Pract. 2013; 13: 604-613
        • Svensson P.
        • Sharav Y.
        • Benoliel R.
        Myalgia, myofascial pain, tension-type headaches, and fibromyalgia.
        in: Sharav Y. Benoliel R. Orofacial pain and headache. 2nd edition. Quintessence Publishing Co, Inc., Chicago2015: 195-256
        • Mense S.
        The pathogenesis of muscle pain.
        Curr Pain Headache Rep. 2003; 7: 419-425
        • Slade G.D.
        • Ohrbach R.
        • Greenspan J.D.
        • et al.
        Painful temporomandibular disorder: decade of discovery from OPPERA studies.
        J Dent Res. 2016; 95: 1084-1092
        • Kalladka M.
        • Young A.
        • Khan J.
        Myofascial pain in temporomandibular disorders: Updates on etiopathogenesis and management.
        J Bodyw Mov Ther. 2021; 28: 104-113
        • Leite F.M.
        • Atallah A.N.
        • El Dib R.
        • et al.
        Cyclobenzaprine for the treatment of myofascial pain in adults.
        Cochrane Database Syst Rev. 2009; : CD006830
        • Honda M.
        • Nishida T.
        • Ono H.
        Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT2 receptors.
        Eur J Pharmacol. 2003; 458: 91-99
        • Keith D.A.
        • Hernández-Nuño de la Rosa M.F.
        Special screening resources: strategies to identify substance use disorders, including opioid misuse and abuse.
        Dental Clin. 2020; 64: 513-524
        • Fricton J.
        • Look J.O.
        • Wright E.
        • et al.
        Systematic review and meta-analysis of randomized controlled trials evaluating intraoral orthopedic appliances for temporomandibular disorders.
        J Orofac Pain. 2010; 24: 237-254
        • Al-Moraissi E.A.
        • Farea R.
        • Qasem K.A.
        • et al.
        Effectiveness of occlusal splint therapy in the management of temporomandibular disorders: network meta-analysis of randomized controlled trials.
        Int J Oral Maxillofac Surg. 2020; 49: 1042-1056
        • Reiter S.
        • Eli I.
        • Mahameed M.
        • et al.
        Pain catastrophizing and pain persistence in temporomandibular disorder patients.
        J Oral Facial Pain Headache. 2018; 32: 309-320
        • Williams A.C.C.
        • Fisher E.
        • Hearn L.
        • et al.
        Psychological therapies for the management of chronic pain (excluding headache) in adults.
        Cochrane Database Syst Rev. 2020; 8: CD007407
        • Walker J.W.
        • Shah B.J.
        Trigger point injections: a systematic, narrative review of the current literature.
        SN Compr Clin Med. 2020; 2: 746-752
        • Iwama H.
        • Akama Y.
        The superiority of water-diluted 0.25% to neat 1% lidocaine for trigger-point injections in myofascial pain syndrome: a prospective, randomized, double-blinded trial.
        Anesth Analg. 2000; 91: 408-409
        • Borg-Stein J.
        • Iaccarino M.A.
        Myofascial pain syndrome treatments.
        Phys Med Rehabil Clin N Am. 2014; 25: 357-374
        • Khawaja S.N.
        • Scrivani S.J.
        • Holland N.
        • et al.
        Effectiveness, safety, and predictors of response to botulinum toxin type a in refractory masticatory myalgia: a retrospective study.
        J Oral Maxillofac Surg. 2017; 75: 2307-2315
        • Herd C.P.
        • Tomlinson C.L.
        • Rick C.
        • et al.
        Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.
        BMJ Open. 2019; 9: e027953